TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02800603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up
Description: The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings.
Study: NCT02855359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT02798029

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Frameless Fractionated Stereotactic Radiation Therapy
Study: NCT02855359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
Study: NCT03572530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-AZA) group 1
Description: 5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-AZA) group 2
Description: 5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-AZA) group 3
Description: 5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks.
Study: NCT01482143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study: NCT01773161

Intervention type: PROCEDURE
Intervention: Cerebral palsy, post hip surgery
Description: All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
Study: NCT01068210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Stretching
Description: The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
Study: NCT02567734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous irreversible electroporation
Description: Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
Study: NCT02657057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS
Description: The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS SNS
Description: Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
Study: NCT03465774

Intervention type: DRUG
Intervention: Doxycycline
Description: Receive via IPC

Intervention type: DEVICE
Intervention: Indwelling Catheter
Description: Receive IPC

Intervention type: DEVICE
Intervention: Indwelling Catheter
Description: Receive IPC

Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03155178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep
Description: Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
Study: NCT04263896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Participants will take 1 17g pack per day for 10 days preceding surgery.
Study: NCT02548351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03098498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival Debridement
Description: Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival Debridement
Description: Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
Study: NCT03329170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention using motivational interviewing
Description: A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is \<12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
Study: NCT03250390

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of volatile organic compounds during exhalation
Description: The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of volatile organic compounds during exhalation
Description: The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)
Study: NCT01005823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 29102 cream
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 29102 cream
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 29102 cream
Description: Twice daily application for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102 placebo cream
Description: LEO 29102 placebo cream
Study: NCT02118142

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine
Description: 6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: 6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
Study: NCT01790828

Intervention type: DRUG
Intervention: Xyntha : coagulation factor IIIV (recombinant)
Description: Xyntha will be administered according to physician's discretion.
Study: NCT03185754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Description: Sublobar resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy
Description: lobectomy
Study: NCT04139512

Intervention type: PROCEDURE
Group type: OTHER
Intervention: guided surgery
Description: placement of implant with local anesthesia using full guided surgery protocol versus free- hande one

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventionnel implant placement
Description: placement of dental implant with conventionnal freehand technic
Study: NCT03069599

Intervention type: PROCEDURE
Intervention: irreversible electroporation (IRE)
Description: Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.

Intervention type: PROCEDURE
Intervention: irreversible electroporation (IRE)
Description: Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
Study: NCT04190511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic-containing dairy
Description: The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
Study: NCT03050736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083 (Dianhydrogalactitol)
Description: VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
Study: NCT04216693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive the digoxin-like placebo treatment.
Study: NCT00960986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: po, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: po, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: po, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: po, QD
Study: NCT03492814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial wound closure
Description: 3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total wound closure
Description: 5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
Study: NCT02014233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Study: NCT00639444

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten-free, normocaloric diet from 6 to 12 months
Description: Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
Study: NCT03627338

Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire, interview
Description: questionaire, interview

Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire, interview
Description: questionaire, interview

Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire, interview
Description: questionaire, interview
Study: NCT03310801

Intervention type: PROCEDURE
Intervention: ACP or Watchman
Description: Left atrial appnedage occlusion using ACP or Watchman
Study: NCT02171013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran polymorph I
Study: NCT00921102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: 200 µg of a 200 µg/ml solution, intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 200 µg of a 200 µg/ml solution, intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 200 µg of a 200 µg/ml solution, intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline solution
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline solution
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: 100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine
Study: NCT01302444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 40mg for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks